ASAndreas Stensvold

Andreas Stensvold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andreas Stensvold has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tangible Interactions for Pain Assessment in Palliative Care

    by Louise Sandal Løkeland, Frode Guribye, Andreas Stensvold, Ingvald Grindheim

    Extensive pain is a common reality for cancer patients, which requires proactive assessment and management from healthcare professionals. Clinical pain assessment commonly relies on quantification to construct quasi-objective measures for documenting and communicating pain experiences. Here, self-reporting through numeric or verbal scales is the gold standard for indicating pain intensity. However, there is a need for non-intrusive tools for easily repeatable, in situ pain assessments. We explore using a tangible pain assessment system, Grasp, for self-reporting and assessing pain in palliative care. In a field trial with 34 patients and 4 nurses, we examined how tangible interaction facilitates repeated self-reporting of pain experiences and how visualizations of these interactions encourage communication between nurses and patients during pain assessment. Our study highlights how combining multi-dimensional pain reporting through tangible interaction and visualizations can support existing practices and contribute to a holistic, dynamic understanding of patients’ experiences by supporting conversations and event recall.


  • Open Access

    Anticancer therapy at end-of-life: A retrospective cohort study

    by Johnny Singh, Andreas Stensvold, Martin Turzer, Ellen Karine Grov

    Background: A significant proportion of patients with incurable cancer receive systemic anticancer therapy (SACT) within their last 30 days of life (DOL). The treatment has questionable benefit, nevertheless is considered a quality indicator of end-of-life (EOL) care. This retrospective cohort study aims to investigate the rates and potential predictors of SACT and factors associated with SACT within the last 30 DOL. The study also evaluates the scope of Eastern Cooperative Oncology Group (ECOG) performance status and the modified Glasgow prognostic score (mGPS) as decision-making tools for oncologists. Patients and Material: This review of medical records included 383 patients with non-curable cancer who died between July 2018 and December 2019. Descriptive statistics with Chi-squared tests and regression analysis were used to identify factors associated with SACT within the last 30 DOL. Results: Fifty-seven (15%) patients received SACT within the last 30 DOL. SACT within 30 last DOL was associated with shorter time from diagnosis until death (median 234 days vs. 482, p = 0.008) and ECOG score < 3 30 days prior to death (p = 0.001). Patients receiving SACT during the last 30 DOL were more likely to be hospitalised and die in hospital. ECOG and mGPS score were stated at start last line of treatment only in 139 (51%) and 135 (49%) respectively. Interpretation: Those with short time since diagnosis tended to receive SACT more frequently the last 30 DOL. The use of mGPS as a decision-making tool is modest, and there is lack in documentation of performance status.


  • Open Access

    Hospitalizations and re-hospitalizations at the end-of-life among cancer patients; a retrospective register data study

    by J. Singh, E. K. Grov, M. Turzer, A. Stensvold

    Background: Patients with incurable cancer are frequently hospitalized within their last 30 days of life (DOL) due to numerous symptoms and concerns. These hospitalizations can be burdensome for the patient and the caregivers and are therefore considered a quality indicator of end-of-life care. This retrospective cohort study aims to investigate the rates and potential predictors of hospitalizations and re-hospitalizations within the last 30 DOL. Methods: This register data study included 383 patients with non-curable cancer who died in the pre-covid period between July 2018 and December 2019. Descriptive statistics with Chi-squared tests for the categorical data and logistic regression analysis were used to identify factors associated with hospitalization within the last 30 DOL. Results: A total of 272 (71%) had hospitalizations within the last 30 days of life and 93 (24%) had > 1 hospitalizations. Hospitalization was associated with shorter time from palliative care unit (PCU) referral to death, male gender, age < 80 years and systemic anticancer therapy (SACT) within the last 30 DOL. The most common treatment approaches initiated during re-hospitalizations remained treatment for suspected or confirmed infection (45%), pleural or abdominal paracentesis (20%) and erythrocytes transfusion (18%). Conclusion: Hospitalization and re-hospitalization within the last 30 DOL were associated with male gender, age below 80, systemic anticancer therapy and suspected or confirmed infection.


  • Long-term predictive value of serum PSA values obtained in clinical practice – Results from the Norwegian Prostate Cancer Consortium (NPCC)

    by S. Carlsson, J. Bjerner, H. Lilja, K. Aas, S.D. Fosså, C. Müller, S. Müller, A. Stensvold, O. Thomas, O.D. Røe, et al.

  • Potentially Curative Radiotherapy for Non–Small-Cell Lung Cancer in Norway: A Population-Based Study of Survival

    by Trond-Eirik Strand, Paal Fredrik Brunsvig, Dag Clement Johannessen, Stein Sundstrøm, Mari Wang, Kjersti Hornslien, Roy Martin Bremnes, Andreas Stensvold, Oddveig Garpestad, Jarle Norstein